Hi, my name is Jonathan Goffman. I'm a professor at Emory University in Atlanta, Georgia, and I'm here at ASH 2025 in Orlando. And I am presenting data on the characteristics of patients with newly diagnosed myeloma who are fit, who had four drug induction therapy with a combination of deritumab, let alone myobortezumab and dexamethasone. And we collaborated with our colleagues in Athens, Greece, and we asked the question, what are the outcomes and what are the characteristics of patients, not who do very, very well, but who fail to achieve a VGPR, a very good partial response? And so we combine the data. We have approximately, we have close to 450 patients between our two data sets, and we identified a subgroup of patients who with induction therapy, that is their first four cycles or so of therapy, failed to achieve a very good partial response. And it was very interesting, we identified two cytogenetic factors that were associated with failure to achieve a VGPR. One that I think a lot of people would predict in patients who had deletion 17P, and the second one was those patients who had translocation 1114 or T1114. We then asked the question of these patients who failed to achieve a VGPR with induction therapy, what was their subsequent outcome from a progression-free survival and overall survival standpoint? Again, as we predicted, those patients who had the high-recited genetic abnormality of deletion 17P, their outcomes from both progression-free survival and overall survival were decreased compared to the rest of the patient population. In contrast, those patients who had the translocation 1114, T1114, and failed to achieve a VGPR, they did not have any decrease in their progression-free or overall survival. In addition, we looked at the very small fraction of patients who failed to achieve a VGPR after transplant and their best response was failure to achieve a VGPR. And again, we showed the same pattern. Those individuals who failed to achieve a VGPR with deletion 17P had a significantly decreased progression-free and overall survival. Whereas even after transplant, in their best response, those individuals with 1114 who failed to achieve a VGPR did not have a decrease in their progression-free and overall survival. Why is this data so important? Because it's important to know what the underlying cytogenetics are, whether it's deletion 17P or likely other high-risk cytogenetics versus 1114 after induction therapy and those patients who failed to achieve a major response. The data argues that we should likely do something different for those patients with deletion 17P because we know their outcomes are less than what we want. Whereas those patients with 1114, we should continue on their therapy because even though they had less of a response, their outcome remained very good. the difference, and we're deeply grateful for your support.
HealthTree • December 21, 2025